Loading…

Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis

Acute kidney injury (AKI), characterized by a sudden decline in kidney function involving tubular damage and epithelial cell death, can lead to progressive tissue fibrosis and chronic kidney disease due to interstitial fibroblast activation and tissue repair failures that lack direct treatments. Aft...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2024-08, Vol.177, p.116923, Article 116923
Main Authors: Perez-Moreno, Elisa, Toledo, Tomás, Campusano, Pascale, Zuñiga, Sebastián, Azócar, Lorena, Feuerhake, Teo, Méndez, Gonzalo P., Labarca, Mariana, Pérez-Molina, Francisca, de la Peña, Adely, Herrera-Cid, Cristian, Ehrenfeld, Pamela, Godoy, Alejandro S., González, Alfonso, Soza, Andrea
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c287t-3bfa117a9cf206c2938f1156e204e782a717255a609162a94639c7e78382f8083
container_end_page
container_issue
container_start_page 116923
container_title Biomedicine & pharmacotherapy
container_volume 177
creator Perez-Moreno, Elisa
Toledo, Tomás
Campusano, Pascale
Zuñiga, Sebastián
Azócar, Lorena
Feuerhake, Teo
Méndez, Gonzalo P.
Labarca, Mariana
Pérez-Molina, Francisca
de la Peña, Adely
Herrera-Cid, Cristian
Ehrenfeld, Pamela
Godoy, Alejandro S.
González, Alfonso
Soza, Andrea
description Acute kidney injury (AKI), characterized by a sudden decline in kidney function involving tubular damage and epithelial cell death, can lead to progressive tissue fibrosis and chronic kidney disease due to interstitial fibroblast activation and tissue repair failures that lack direct treatments. After an AKI episode, surviving renal tubular cells undergo cycles of dedifferentiation, proliferation and redifferentiation while fibroblast activity increases and then declines to avoid an exaggerated extracellular matrix deposition. Appropriate tissue recovery versus pathogenic fibrotic progression depends on fine-tuning all these processes. Identifying endogenous factors able to affect any of them may offer new therapeutic opportunities to improve AKI outcomes. Galectin-8 (Gal-8) is an endogenous carbohydrate-binding protein that is secreted through an unconventional mechanism, binds to glycosylated proteins at the cell surface and modifies various cellular activities, including cell proliferation and survival against stress conditions. Here, using a mouse model of AKI induced by folic acid, we show that pre-treatment with Gal-8 protects against cell death, promotes epithelial cell redifferentiation and improves renal function. In addition, Gal-8 decreases fibroblast activation, resulting in less expression of fibrotic genes. Gal-8 added after AKI induction is also effective in maintaining renal function against damage, improving epithelial cell survival. The ability to protect kidneys from injury during both pre- and post-treatments, coupled with its anti-fibrotic effect, highlights Gal-8 as an endogenous factor to be considered in therapeutic strategies aimed at improving renal function and mitigating chronic pathogenic progression. [Display omitted] •Gal-8 preserves kidney function in folic acid-induced AKI.•Gal-8 reduces acute renal cortical damage in folic acid-induced AKI.•Gal-8 has an anti-fibrotic effect in folic acid-induced kidney injury.•Gal-8 decreases fibroblast activation in folic acid-induced kidney injury.
doi_str_mv 10.1016/j.biopha.2024.116923
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3073231471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332224008072</els_id><sourcerecordid>3073231471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-3bfa117a9cf206c2938f1156e204e782a717255a609162a94639c7e78382f8083</originalsourceid><addsrcrecordid>eNp9kMlqHDEQhoVJsMdO3iAEHXPpiZZuLZdAMN7AkEtyFhp1NalJjzSR1IZ5-8i0naMPRVHU_9fyEfKJsy1nXH3db3eYjr_9VjDRbzlXVsgzsuF2YJ1iTL8jG6YH2UkpxAW5LGXPGBuUNOfkQhorFbdiQ-DOzxAqxs7QkJZYIftQC53SjIH6gGOHcVwCjK1YKtA_OEY4UYz7JZ-ojyM9ZniC2DzYomYfC1ZMkdZEJ9zlVLB8IO8nPxf4-JKvyK_bm5_X993jj7uH6--PXRBG107uJs-59jZMgqkgrDQT54MCwXrQRnjNtRgGr5jlSnjbK2mDbh1pxGSYkVfkyzr3mNPfBUp1BywB5tlHSEtxkmkpJO81b9J-lYZ2YckwuWPGg88nx5l7Buz2bgXsngG7FXCzfX7ZsOwOMP43vRJtgm-rANqfTwjZlYAQG0DMDbQbE7694R-aMI2a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073231471</pqid></control><display><type>article</type><title>Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Perez-Moreno, Elisa ; Toledo, Tomás ; Campusano, Pascale ; Zuñiga, Sebastián ; Azócar, Lorena ; Feuerhake, Teo ; Méndez, Gonzalo P. ; Labarca, Mariana ; Pérez-Molina, Francisca ; de la Peña, Adely ; Herrera-Cid, Cristian ; Ehrenfeld, Pamela ; Godoy, Alejandro S. ; González, Alfonso ; Soza, Andrea</creator><creatorcontrib>Perez-Moreno, Elisa ; Toledo, Tomás ; Campusano, Pascale ; Zuñiga, Sebastián ; Azócar, Lorena ; Feuerhake, Teo ; Méndez, Gonzalo P. ; Labarca, Mariana ; Pérez-Molina, Francisca ; de la Peña, Adely ; Herrera-Cid, Cristian ; Ehrenfeld, Pamela ; Godoy, Alejandro S. ; González, Alfonso ; Soza, Andrea</creatorcontrib><description>Acute kidney injury (AKI), characterized by a sudden decline in kidney function involving tubular damage and epithelial cell death, can lead to progressive tissue fibrosis and chronic kidney disease due to interstitial fibroblast activation and tissue repair failures that lack direct treatments. After an AKI episode, surviving renal tubular cells undergo cycles of dedifferentiation, proliferation and redifferentiation while fibroblast activity increases and then declines to avoid an exaggerated extracellular matrix deposition. Appropriate tissue recovery versus pathogenic fibrotic progression depends on fine-tuning all these processes. Identifying endogenous factors able to affect any of them may offer new therapeutic opportunities to improve AKI outcomes. Galectin-8 (Gal-8) is an endogenous carbohydrate-binding protein that is secreted through an unconventional mechanism, binds to glycosylated proteins at the cell surface and modifies various cellular activities, including cell proliferation and survival against stress conditions. Here, using a mouse model of AKI induced by folic acid, we show that pre-treatment with Gal-8 protects against cell death, promotes epithelial cell redifferentiation and improves renal function. In addition, Gal-8 decreases fibroblast activation, resulting in less expression of fibrotic genes. Gal-8 added after AKI induction is also effective in maintaining renal function against damage, improving epithelial cell survival. The ability to protect kidneys from injury during both pre- and post-treatments, coupled with its anti-fibrotic effect, highlights Gal-8 as an endogenous factor to be considered in therapeutic strategies aimed at improving renal function and mitigating chronic pathogenic progression. [Display omitted] •Gal-8 preserves kidney function in folic acid-induced AKI.•Gal-8 reduces acute renal cortical damage in folic acid-induced AKI.•Gal-8 has an anti-fibrotic effect in folic acid-induced kidney injury.•Gal-8 decreases fibroblast activation in folic acid-induced kidney injury.</description><identifier>ISSN: 0753-3322</identifier><identifier>ISSN: 1950-6007</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2024.116923</identifier><identifier>PMID: 38936192</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Acute kidney injury ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - drug therapy ; Acute Kidney Injury - metabolism ; Acute Kidney Injury - pathology ; Acute Kidney Injury - prevention &amp; control ; AKI-to-CKD transition ; Animals ; Disease Models, Animal ; Disease Progression ; Epithelial Cells - drug effects ; Epithelial Cells - metabolism ; Epithelial Cells - pathology ; Epithelial-mesenchymal plasticity ; Epithelial-mesenchymal transition ; Fibroblasts - drug effects ; Fibroblasts - metabolism ; Fibroblasts - pathology ; Fibrosis ; Folic acid ; Folic Acid - pharmacology ; Galectin-8 ; Galectins - metabolism ; Kidney - drug effects ; Kidney - metabolism ; Kidney - pathology ; Male ; Mice ; Mice, Inbred C57BL</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2024-08, Vol.177, p.116923, Article 116923</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c287t-3bfa117a9cf206c2938f1156e204e782a717255a609162a94639c7e78382f8083</cites><orcidid>0000-0002-2588-3925 ; 0000-0003-3783-5231 ; 0000-0002-2519-7570 ; 0000-0001-6455-3569 ; 0000-0002-2010-4785 ; 0000-0003-1697-1058</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38936192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perez-Moreno, Elisa</creatorcontrib><creatorcontrib>Toledo, Tomás</creatorcontrib><creatorcontrib>Campusano, Pascale</creatorcontrib><creatorcontrib>Zuñiga, Sebastián</creatorcontrib><creatorcontrib>Azócar, Lorena</creatorcontrib><creatorcontrib>Feuerhake, Teo</creatorcontrib><creatorcontrib>Méndez, Gonzalo P.</creatorcontrib><creatorcontrib>Labarca, Mariana</creatorcontrib><creatorcontrib>Pérez-Molina, Francisca</creatorcontrib><creatorcontrib>de la Peña, Adely</creatorcontrib><creatorcontrib>Herrera-Cid, Cristian</creatorcontrib><creatorcontrib>Ehrenfeld, Pamela</creatorcontrib><creatorcontrib>Godoy, Alejandro S.</creatorcontrib><creatorcontrib>González, Alfonso</creatorcontrib><creatorcontrib>Soza, Andrea</creatorcontrib><title>Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Acute kidney injury (AKI), characterized by a sudden decline in kidney function involving tubular damage and epithelial cell death, can lead to progressive tissue fibrosis and chronic kidney disease due to interstitial fibroblast activation and tissue repair failures that lack direct treatments. After an AKI episode, surviving renal tubular cells undergo cycles of dedifferentiation, proliferation and redifferentiation while fibroblast activity increases and then declines to avoid an exaggerated extracellular matrix deposition. Appropriate tissue recovery versus pathogenic fibrotic progression depends on fine-tuning all these processes. Identifying endogenous factors able to affect any of them may offer new therapeutic opportunities to improve AKI outcomes. Galectin-8 (Gal-8) is an endogenous carbohydrate-binding protein that is secreted through an unconventional mechanism, binds to glycosylated proteins at the cell surface and modifies various cellular activities, including cell proliferation and survival against stress conditions. Here, using a mouse model of AKI induced by folic acid, we show that pre-treatment with Gal-8 protects against cell death, promotes epithelial cell redifferentiation and improves renal function. In addition, Gal-8 decreases fibroblast activation, resulting in less expression of fibrotic genes. Gal-8 added after AKI induction is also effective in maintaining renal function against damage, improving epithelial cell survival. The ability to protect kidneys from injury during both pre- and post-treatments, coupled with its anti-fibrotic effect, highlights Gal-8 as an endogenous factor to be considered in therapeutic strategies aimed at improving renal function and mitigating chronic pathogenic progression. [Display omitted] •Gal-8 preserves kidney function in folic acid-induced AKI.•Gal-8 reduces acute renal cortical damage in folic acid-induced AKI.•Gal-8 has an anti-fibrotic effect in folic acid-induced kidney injury.•Gal-8 decreases fibroblast activation in folic acid-induced kidney injury.</description><subject>Acute kidney injury</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - drug therapy</subject><subject>Acute Kidney Injury - metabolism</subject><subject>Acute Kidney Injury - pathology</subject><subject>Acute Kidney Injury - prevention &amp; control</subject><subject>AKI-to-CKD transition</subject><subject>Animals</subject><subject>Disease Models, Animal</subject><subject>Disease Progression</subject><subject>Epithelial Cells - drug effects</subject><subject>Epithelial Cells - metabolism</subject><subject>Epithelial Cells - pathology</subject><subject>Epithelial-mesenchymal plasticity</subject><subject>Epithelial-mesenchymal transition</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - metabolism</subject><subject>Fibroblasts - pathology</subject><subject>Fibrosis</subject><subject>Folic acid</subject><subject>Folic Acid - pharmacology</subject><subject>Galectin-8</subject><subject>Galectins - metabolism</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><issn>0753-3322</issn><issn>1950-6007</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMlqHDEQhoVJsMdO3iAEHXPpiZZuLZdAMN7AkEtyFhp1NalJjzSR1IZ5-8i0naMPRVHU_9fyEfKJsy1nXH3db3eYjr_9VjDRbzlXVsgzsuF2YJ1iTL8jG6YH2UkpxAW5LGXPGBuUNOfkQhorFbdiQ-DOzxAqxs7QkJZYIftQC53SjIH6gGOHcVwCjK1YKtA_OEY4UYz7JZ-ojyM9ZniC2DzYomYfC1ZMkdZEJ9zlVLB8IO8nPxf4-JKvyK_bm5_X993jj7uH6--PXRBG107uJs-59jZMgqkgrDQT54MCwXrQRnjNtRgGr5jlSnjbK2mDbh1pxGSYkVfkyzr3mNPfBUp1BywB5tlHSEtxkmkpJO81b9J-lYZ2YckwuWPGg88nx5l7Buz2bgXsngG7FXCzfX7ZsOwOMP43vRJtgm-rANqfTwjZlYAQG0DMDbQbE7694R-aMI2a</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Perez-Moreno, Elisa</creator><creator>Toledo, Tomás</creator><creator>Campusano, Pascale</creator><creator>Zuñiga, Sebastián</creator><creator>Azócar, Lorena</creator><creator>Feuerhake, Teo</creator><creator>Méndez, Gonzalo P.</creator><creator>Labarca, Mariana</creator><creator>Pérez-Molina, Francisca</creator><creator>de la Peña, Adely</creator><creator>Herrera-Cid, Cristian</creator><creator>Ehrenfeld, Pamela</creator><creator>Godoy, Alejandro S.</creator><creator>González, Alfonso</creator><creator>Soza, Andrea</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2588-3925</orcidid><orcidid>https://orcid.org/0000-0003-3783-5231</orcidid><orcidid>https://orcid.org/0000-0002-2519-7570</orcidid><orcidid>https://orcid.org/0000-0001-6455-3569</orcidid><orcidid>https://orcid.org/0000-0002-2010-4785</orcidid><orcidid>https://orcid.org/0000-0003-1697-1058</orcidid></search><sort><creationdate>202408</creationdate><title>Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis</title><author>Perez-Moreno, Elisa ; Toledo, Tomás ; Campusano, Pascale ; Zuñiga, Sebastián ; Azócar, Lorena ; Feuerhake, Teo ; Méndez, Gonzalo P. ; Labarca, Mariana ; Pérez-Molina, Francisca ; de la Peña, Adely ; Herrera-Cid, Cristian ; Ehrenfeld, Pamela ; Godoy, Alejandro S. ; González, Alfonso ; Soza, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-3bfa117a9cf206c2938f1156e204e782a717255a609162a94639c7e78382f8083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute kidney injury</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - drug therapy</topic><topic>Acute Kidney Injury - metabolism</topic><topic>Acute Kidney Injury - pathology</topic><topic>Acute Kidney Injury - prevention &amp; control</topic><topic>AKI-to-CKD transition</topic><topic>Animals</topic><topic>Disease Models, Animal</topic><topic>Disease Progression</topic><topic>Epithelial Cells - drug effects</topic><topic>Epithelial Cells - metabolism</topic><topic>Epithelial Cells - pathology</topic><topic>Epithelial-mesenchymal plasticity</topic><topic>Epithelial-mesenchymal transition</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - metabolism</topic><topic>Fibroblasts - pathology</topic><topic>Fibrosis</topic><topic>Folic acid</topic><topic>Folic Acid - pharmacology</topic><topic>Galectin-8</topic><topic>Galectins - metabolism</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perez-Moreno, Elisa</creatorcontrib><creatorcontrib>Toledo, Tomás</creatorcontrib><creatorcontrib>Campusano, Pascale</creatorcontrib><creatorcontrib>Zuñiga, Sebastián</creatorcontrib><creatorcontrib>Azócar, Lorena</creatorcontrib><creatorcontrib>Feuerhake, Teo</creatorcontrib><creatorcontrib>Méndez, Gonzalo P.</creatorcontrib><creatorcontrib>Labarca, Mariana</creatorcontrib><creatorcontrib>Pérez-Molina, Francisca</creatorcontrib><creatorcontrib>de la Peña, Adely</creatorcontrib><creatorcontrib>Herrera-Cid, Cristian</creatorcontrib><creatorcontrib>Ehrenfeld, Pamela</creatorcontrib><creatorcontrib>Godoy, Alejandro S.</creatorcontrib><creatorcontrib>González, Alfonso</creatorcontrib><creatorcontrib>Soza, Andrea</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perez-Moreno, Elisa</au><au>Toledo, Tomás</au><au>Campusano, Pascale</au><au>Zuñiga, Sebastián</au><au>Azócar, Lorena</au><au>Feuerhake, Teo</au><au>Méndez, Gonzalo P.</au><au>Labarca, Mariana</au><au>Pérez-Molina, Francisca</au><au>de la Peña, Adely</au><au>Herrera-Cid, Cristian</au><au>Ehrenfeld, Pamela</au><au>Godoy, Alejandro S.</au><au>González, Alfonso</au><au>Soza, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2024-08</date><risdate>2024</risdate><volume>177</volume><spage>116923</spage><pages>116923-</pages><artnum>116923</artnum><issn>0753-3322</issn><issn>1950-6007</issn><eissn>1950-6007</eissn><abstract>Acute kidney injury (AKI), characterized by a sudden decline in kidney function involving tubular damage and epithelial cell death, can lead to progressive tissue fibrosis and chronic kidney disease due to interstitial fibroblast activation and tissue repair failures that lack direct treatments. After an AKI episode, surviving renal tubular cells undergo cycles of dedifferentiation, proliferation and redifferentiation while fibroblast activity increases and then declines to avoid an exaggerated extracellular matrix deposition. Appropriate tissue recovery versus pathogenic fibrotic progression depends on fine-tuning all these processes. Identifying endogenous factors able to affect any of them may offer new therapeutic opportunities to improve AKI outcomes. Galectin-8 (Gal-8) is an endogenous carbohydrate-binding protein that is secreted through an unconventional mechanism, binds to glycosylated proteins at the cell surface and modifies various cellular activities, including cell proliferation and survival against stress conditions. Here, using a mouse model of AKI induced by folic acid, we show that pre-treatment with Gal-8 protects against cell death, promotes epithelial cell redifferentiation and improves renal function. In addition, Gal-8 decreases fibroblast activation, resulting in less expression of fibrotic genes. Gal-8 added after AKI induction is also effective in maintaining renal function against damage, improving epithelial cell survival. The ability to protect kidneys from injury during both pre- and post-treatments, coupled with its anti-fibrotic effect, highlights Gal-8 as an endogenous factor to be considered in therapeutic strategies aimed at improving renal function and mitigating chronic pathogenic progression. [Display omitted] •Gal-8 preserves kidney function in folic acid-induced AKI.•Gal-8 reduces acute renal cortical damage in folic acid-induced AKI.•Gal-8 has an anti-fibrotic effect in folic acid-induced kidney injury.•Gal-8 decreases fibroblast activation in folic acid-induced kidney injury.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38936192</pmid><doi>10.1016/j.biopha.2024.116923</doi><orcidid>https://orcid.org/0000-0002-2588-3925</orcidid><orcidid>https://orcid.org/0000-0003-3783-5231</orcidid><orcidid>https://orcid.org/0000-0002-2519-7570</orcidid><orcidid>https://orcid.org/0000-0001-6455-3569</orcidid><orcidid>https://orcid.org/0000-0002-2010-4785</orcidid><orcidid>https://orcid.org/0000-0003-1697-1058</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2024-08, Vol.177, p.116923, Article 116923
issn 0753-3322
1950-6007
1950-6007
language eng
recordid cdi_proquest_miscellaneous_3073231471
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Acute kidney injury
Acute Kidney Injury - chemically induced
Acute Kidney Injury - drug therapy
Acute Kidney Injury - metabolism
Acute Kidney Injury - pathology
Acute Kidney Injury - prevention & control
AKI-to-CKD transition
Animals
Disease Models, Animal
Disease Progression
Epithelial Cells - drug effects
Epithelial Cells - metabolism
Epithelial Cells - pathology
Epithelial-mesenchymal plasticity
Epithelial-mesenchymal transition
Fibroblasts - drug effects
Fibroblasts - metabolism
Fibroblasts - pathology
Fibrosis
Folic acid
Folic Acid - pharmacology
Galectin-8
Galectins - metabolism
Kidney - drug effects
Kidney - metabolism
Kidney - pathology
Male
Mice
Mice, Inbred C57BL
title Galectin-8 counteracts folic acid-induced acute kidney injury and prevents its transition to fibrosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T10%3A09%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Galectin-8%20counteracts%20folic%20acid-induced%20acute%20kidney%20injury%20and%20prevents%20its%20transition%20to%20fibrosis&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Perez-Moreno,%20Elisa&rft.date=2024-08&rft.volume=177&rft.spage=116923&rft.pages=116923-&rft.artnum=116923&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2024.116923&rft_dat=%3Cproquest_cross%3E3073231471%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c287t-3bfa117a9cf206c2938f1156e204e782a717255a609162a94639c7e78382f8083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3073231471&rft_id=info:pmid/38936192&rfr_iscdi=true